Sanofi Introduces Breakthrough Rilzabrutinib for the Treatment of Warm Autoimmune Haemolytic Anaemia
Sanofi has introduced rilzabrutinib for the treatment of patients with warm autoimmune haemolytic anaemia (wAIHA), a rare autoimmune disorder characterised by the destruction of red blood cells.
Rilzabrutinib is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor designed to regulate immune responses involved in autoimmune and inflammatory conditions. By targeting BTK activity in immune cells, the therapy aims to restore immune balance and reduce the premature destruction of red blood cells associated with wAIHA.
The Breakthrough Therapy Designation from the U.S. Food and Drug Administration and orphan drug status in Japan are supported by clinical data from the ongoing LUMINA 2 Phase 2b study, which is evaluating the safety and efficacy of rilzabrutinib in patients with warm autoimmune haemolytic anaemia. In addition, the LUMINA 3 Phase 3 study is currently assessing rilzabrutinib in comparison with placebo in patients with the condition. These regulatory designations are intended to support the accelerated development of therapies addressing serious diseases with limited treatment options.
Rilzabrutinib had previously received orphan drug designation from the U.S. Food and Drug Administration for autoimmune haemolytic anaemia, as well as for other rare conditions including IgG4-related disease and sickle cell disease. The therapy has also been granted FDA fast track designation for immune thrombocytopenia (ITP) and IgG4-related disease, along with orphan designation in the European Union for ITP, autoimmune haemolytic anaemia and IgG4-related disease.
Warm autoimmune haemolytic anaemia is a rare condition caused by immune system dysfunction, where autoantibodies attack and destroy the body’s red blood cells faster than they can be replaced. The disorder can lead to anaemia, fatigue, shortness of breath and other complications, including an increased risk of thromboembolism. The disease affects a small number of patients globally and continues to represent an area of significant unmet medical need.
Rilzabrutinib is currently approved under the brand name Wayrilz in the United States, the European Union and the United Arab Emirates for the treatment of adults with immune thrombocytopenia. Beyond its approved indication, the therapy is being studied across several rare immune-mediated diseases, including warm autoimmune haemolytic anaemia, IgG4-related disease and sickle cell disease, as part of its ongoing clinical development programme.
